"Designing Growth Strategies is in our DNA"

U.S. Cardiac Troponin Market Size, Share & Industry Analysis, By Type (Troponin T and Troponin I), By Indication (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Others), By Setting (Laboratory Testing and Point-of-Care (POC) Testing), By End-user (Hospitals & Clinics, Diagnostic Laboratories, and Homecare Settings & Others), and Country Forecast, 2024-2032

Last Updated: September 30, 2024 | Format: PDF | Report ID: FBI108749

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The U.S. cardiac troponin market size was worth USD 1.11 billion in 2023 and is projected to grow at a CAGR of 8.5% during the forecast period.


Cardiac troponin proteins are pivotal in both cardiac and skeletal muscle contraction. Troponin I and troponin T are cardiac regulatory proteins that govern the calcium-mediated interaction between actin and myosin. They act as specific markers for heart muscle damage and assist in diagnosing various cardiovascular conditions, including heart disease and acute coronary syndrome.


Changes in troponin levels are critical in diagnosing acute myocardial infarction, distinguishing it from chronic conditions such as heart or renal failure.


The COVID-19 pandemic positively affected the cardiac troponin market by increasing testing within the U.S. population. The strong link between COVID-19 and cardiovascular issues led to heightened demand for troponin testing among COVID-19 patients, contributing to market growth.


LATEST TRENDS


Strong Focus on the Development of Technologically Advanced Products 


In recent years, the U.S. cardiac troponin market players are shifting their focus to develop and launch products for troponin protein that can be used in point-of-care settings. The market players are increasingly involved in the introduction of POC tests to fulfill the growing demand by end-users. Moreover, the introduction of high-sensitivity troponin assays is also identified as an upward trend in the market.



  • For instance, Abbott launched the ARCHITECT STAT High Sensitivity Troponin-I blood test, which was approved by the U.S. FDA in September 2019.


DRIVING FACTORS


Rising Prevalence of Cardiovascular Diseases to Drive Demand for Cardiac Troponin Testing


The prevalence of key heart diseases, including coronary heart disease (CHD), stroke, high blood pressure, and others, is rapidly increasing in the country. Cardiac troponin test is often used to determine the severity of damage to the cardiac muscles. Increased levels of this protein in the body are the indicators of a high risk of heart attack or any cardiac-related indication.


The growing demand for this test for diagnosis and management of various cardiovascular diseases is anticipated to propel market growth in the near future.



  • According to the CDC data updated in May 2023, around 805,000 people in the U.S. have a heart attack every year.

  • Similarly, about 1 in 20 adults aged 20 and older in the country have coronary artery disease, which is the most common type of heart disease.                                       


Request a Free sample to learn more about this report.


In the U.S., cardiovascular diseases are the leading cause of death, with coronary heart disease accounting for around 41.2% of deaths attributable to CVD in the country. Hypertension and diabetes are major factors leading to CVD, having around 160 million and 32 million patients, respectively, in 2022.


RESTRAINING FACTORS


Declining Rate of Heart Attack Mortality to Limit Product Adoption


One significant factor impeding the U.S. cardiac troponin market growth is the declining mortality rate associated with heart attacks. According to data published by the American College of Cardiology, the death rate attributed to Coronary Heart Disease (CHD) in the U.S. decreased by 31.8% from 2006 to 2016. Similarly, for cardiovascular diseases, the decline was 18.6%. This continual decrease in mortality rates could negatively affect the adoption of troponin testing products, consequently limiting the market growth in the U.S.


SEGMENTATION


By Type Analysis


Based on type, the market is segmented into troponin T and troponin I.


The troponin I segment dominated the U.S. market in 2022. This type of troponin is deemed a more specific marker for assessing the risk of cardiovascular disease. It is frequently utilized in predicting heart attacks.


On the other hand, the troponin T segment is projected to grow at a comparatively slower rate over the study period. This can be attributed to the supportive regulatory scenario in the country, resulting in increased product approvals in the cardiac troponin market in the U.S.


By Indication Analysis


Based on indication, the market is segmented into congestive heart failure, myocardial infarction, acute coronary syndrome, and others.


In 2022, the acute coronary syndrome segment dominated the U.S. market. Rapidly increasing disease burden due to several factors is majorly driving the segment’s growth. Cardiac troponin is considered the prime diagnostic method for the diagnosis of the disease.


On the other hand, the myocardial infarction segment is anticipated to witness a significant growth over the forecast period. The increasing need for the management of myocardial infarction is expected to boost the segment’s growth.


By Setting Analysis


Based on setting, the market is segmented into laboratory testing and point-of-care (POC) testing.


The laboratory testing segment captured the dominating market share in 2022. Key factors contributing to the dominance of the segment include the fact that troponin tests are easily available in laboratory settings. Additionally, the growing demand for these tests among the patient population also supported the segment growth.


The point-of-care (POC) testing segment is estimated to witness the fastest growth in the near future. Recent new product launches, coupled with the introduction of advanced technologies for cardiac troponin testing, have majorly driven the segment's growth.


By End-user Analysis


Based on end-user, the market is divided into hospitals & clinics, diagnostic laboratories, and homecare settings & others.


In 2022, the hospitals & clinics segment accounted for the largest U.S. cardiac troponin market share. Key factors bolstering the dominance of the segment include a rising number of patient visits to hospitals and clinics for cardiac-related issues. Additionally, increased awareness about cardiovascular diseases among the population is expected to augment segment growth.


Meanwhile, the diagnostic laboratories segment is projected to experience substantial growth throughout the forecast period. The high prevalence of cardiovascular diseases leads to increased demand for troponin testing, thereby positively impacting the segment's growth.


KEY INDUSTRY PLAYERS


The marketspace scenario of the U.S. market is moderately fragmented, featuring a substantial presence of both global and domestic players. No single organization is singularly responsible for the market's future growth.


Key players in the market include F. Hoffmann-La Roche Ltd., Abbott, Siemens Healthcare Private Limited, and Beckman Coulter, Inc. These entities are undertaking various strategic initiatives with an aim to expand their product portfolio.



  • For instance, in June 2023, Abbott's Alinity I Stat High Sensitivity Troponin-I chemiluminescent microparticle immunoassay received separate 510(k) clearance from the U.S. FDA.


Other operating players in the market include PerkinElmer Inc., bioMérieux SA, LifeSign LLC, among others. These companies are adopting strategies such as collaborations with other players to strengthen their market presence.


LIST OF KEY COMPANIES PROFILED:



KEY INDUSTRY DEVELOPMENTS:



  • May 2021: PerkinElmer Inc. completed the acquisition of Immunodiagnostic Systems Holdings PLC to strengthen its presence in the immunodiagnostics segment.

  • April 2021: Roche announced five expanded uses for two Elecsys biomarkers, namely N-terminal pro-brain natriuretic peptide and high-sensitive cardiac troponin T (cTnT-hs) test.

  • September 2019: The U.S. FDA approved Abbott’s ARCHITECT STAT High Sensitivity Troponin-I blood test to help diagnose heart attacks faster.


REPORT COVERAGE


An Infographic Representation of U.S. Cardiac Troponin Market

To get information on various segments, share your queries with us



The market research report provides a detailed analysis of the market. It focuses on key market segments such as type, indication, setting, and end-user. In addition, it includes detailed insights on market dynamics, new product launches, key industry developments such as mergers, partnerships, & acquisitions, and the impact of COVID-19 on the market. The report also consists of several factors that have contributed to the market growth. The report also provides the competitive landscape of the market at the U.S. level.


Report Scope & Segmentation



















































ATTRIBUTE



DETAILS



Study Period



2019-2032



Base Year



2023



Estimated Year



2024



Forecast Period



2024-2032



Historical Period



2019-2022



Growth Rate



CAGR of 8.5% from 2024 to 2032



Unit



Value (USD Billion)



Segmentation



By Type



  • Troponin T

  • Troponin I



By Indication



  • Myocardial Infarction

  • Congestive Heart Failure

  • Acute Coronary Syndrome

  • Others



By Setting



  • Laboratory Testing

  • Point-of-Care (POC) Testing



By End User



  • Hospitals & Clinics

  • Diagnostic Laboratories

  • Homecare Settings & Others






Frequently Asked Questions

Fortune Business Insights says that the U.S. market was worth USD 1.11 billion in 2023.

The market is expected to exhibit a CAGR of 8.5% during the forecast period (2024-2032).

By setting, the laboratory testing segment accounted for a dominating market share in 2022.

Abbott, F. Hoffmann-La Roche Ltd., and Siemens Healthcare Private Limited are some of the major players in the market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts
Speak to an Expert
  • 2019-2032
  • 2023
  • 2019-2022
  • 80
Multi-report Purchase Plan
    A Customized Plan Will be Created Based on the number of reports you wish to purchase
Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X